Abstract: What is common between three drugs – Vioxx (Rofecoxib), Bextra (Valdecoxib) and Ibuprofen? All are Non-Steroidal anti-inflammatory drugs (NSAIDs) associated with cardiovascular risks. First Rofecoxib was withdrawn internationally followed by Valdecoxib by their parent manufacturers due to cardiovascular risk factors. Now recently Ibuprofen has also came under scanner, which raised serious concerns about the safety of long-team use of NSAIDs.
British scientists called for more research into the safety of painkillers after finding more evidence that some of them may increase the risk of heart attacks. A study was carried out by Prof. Julia to determine the comparative risk of myocardial infarction in patients taking selective COX-II (cyclooxygenase-II) inhibitors and other NSAIDs in primary care between 2000 and 2004. Findings of the report are published by Prof. Julia in BMJ in 11th June 2005 issue. Report concluded that there is an increased risk of myocardial infarction associated with current use of Rofecoxib, Diclofenac, and ibuprofen despite adjustment for many potential confounders. |
The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 20057149, Fax: 91-11-26855876
Email:
info@kppub.com /
fpc@vsnl.com, Website:
http://www.kppub.com |
